Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Fineline Cube Jan 14, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study

Fineline Cube Aug 1, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...

Company Drug

Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China

Fineline Cube Aug 1, 2023

China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...

Company

WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023

Fineline Cube Aug 1, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...

Company

HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023

Fineline Cube Aug 1, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...

Policy / Regulatory

Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices

Fineline Cube Aug 1, 2023

The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...

Company

Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results

Fineline Cube Jul 31, 2023

Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...

Company Medical Device

MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia

Fineline Cube Jul 31, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs

Fineline Cube Jul 31, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...

Company Deals

Baidu Health Partners with GSK for Shingles Disease Education Programs in China

Fineline Cube Jul 31, 2023

China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...

Company Drug

Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density

Fineline Cube Jul 31, 2023

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Jul 31, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...

Company Deals

Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira

Fineline Cube Jul 31, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...

Company Drug

Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...

Company Drug

Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA

Fineline Cube Jul 31, 2023

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...

Company Deals

Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol

Fineline Cube Jul 31, 2023

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...

Company Deals

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

Fineline Cube Jul 31, 2023

AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...

Company

AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales

Fineline Cube Jul 31, 2023

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...

Company

Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent

Fineline Cube Jul 31, 2023

France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management

Fineline Cube Jul 31, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NMPA Seeks Public Input on Strengthening Supervision of Medical Device Contract Manufacturing

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) is currently seeking public feedback on the “Opinions on...

Posts pagination

1 … 438 439 440 … 609

Recent updates

  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
  • Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration
  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.